Form 4: Generation Bio CSO Reports Routine Stock Transactions

Generation Bio's Chief Scientific Officer, Phillip Samayoa, reported the scheduled vesting of restricted stock units and related common stock transactions.

Summary

• Phillip Samayoa, Chief Scientific Officer of Generation Bio Co. (GBIO), reported transactions on October 15, 2025, related to his beneficial ownership.
• The transactions involved the vesting of 114 restricted stock units (RSUs), which converted into 114 shares of common stock.
• Concurrently, 34 shares of common stock were disposed of at a price of $6.71 per share, likely to cover tax obligations associated with the RSU vesting.
• Following these transactions, Samayoa beneficially owns 14,138 shares of common stock and 573 restricted stock units.
• All reported share amounts reflect a one-for-10 reverse stock split implemented by Generation Bio Co. on July 21, 2025.
• The original grant of 1,834 restricted stock units occurred on January 20, 2023, with a four-year vesting schedule, including 25% vested on January 15, 2024, and the remainder vesting in equal quarterly installments.

Sentiment

Score: 5

Explanation: The filing reports a routine, scheduled insider transaction related to executive compensation, which is neutral in terms of immediate company sentiment.

Positives

• The vesting of restricted stock units indicates continued employment and long-term incentive alignment between the Chief Scientific Officer and shareholder interests.
• The transaction is a routine part of executive compensation, reflecting a scheduled event rather than an unexpected sale.

Negatives

• A portion of the acquired shares (34 shares) was disposed of, reducing the direct beneficial ownership slightly, though this is a common practice for tax withholding.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event and does not signal a change in company fundamentals or strategy.
• Employees: Reflects standard executive compensation practices, which can be a positive for morale and retention of key personnel.

Next Steps

• Remaining restricted stock units will continue to vest in equal quarterly installments as per the original grant schedule.

Key Dates

Recommendation

This Form 4 reports a routine, scheduled vesting of restricted stock units and subsequent tax-related share disposition by a company officer. Such transactions are part of standard executive compensation and do not typically indicate a change in the company's fundamental prospects or warrant a change in investment recommendation based solely on this filing. Investors should rely on broader financial reports and strategic updates for investment decisions.

Keywords

GBIO, Generation Bio, Form 4, Insider Transaction, Restricted Stock Units, RSU, Phillip Samayoa, Chief Scientific Officer, Stock Vesting